NASDAQ:GOSS
Gossamer Bio Inc. Stock News
$0.620
-0.0169 (-2.65%)
At Close: May 24, 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 10'th May 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
07:46am, Monday, 06'th May 2024
Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.
SAN DIEGO, Calif. & PARMA, Italy--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercializa
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
08:02am, Friday, 03'rd May 2024
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.
07:31am, Tuesday, 12'th Mar 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
10:56am, Thursday, 07'th Mar 2024
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 20
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
10:52pm, Tuesday, 05'th Mar 2024
Gossamer Bio (NASDAQ: GOSS ) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
07:31am, Tuesday, 05'th Mar 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
7 Micro-Cap Stocks That Could Majorly Surprise Investors
02:23pm, Wednesday, 31'st Jan 2024
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable b
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 08'th Jan 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
04:01pm, Wednesday, 13'th Dec 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th Dec 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
07:01am, Tuesday, 05'th Dec 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
07:01am, Wednesday, 29'th Nov 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
